首页> 外文会议>IMAPS/ACerS International Conference and Exhibition on Ceramic Interconnect and Ceramic Microsystems Technologies >LTCC MICROREACTORS APPLICATION IN A MICROFLUIDIC INTEGRATED SYSTEM FOR HYDROPHOBIC DRUG ENCAPSULATION IN POLYMERIC NANO/MICROPARTICLES
【24h】

LTCC MICROREACTORS APPLICATION IN A MICROFLUIDIC INTEGRATED SYSTEM FOR HYDROPHOBIC DRUG ENCAPSULATION IN POLYMERIC NANO/MICROPARTICLES

机译:LTCC MicroreActors在聚合物纳米/微粒中的疏水药物包封的微流体集成系统中的应用

获取原文
获取外文期刊封面目录资料

摘要

Nanotechnology develops methods and processes for Drug Delivery Systems (DDS) based on the fabrication of polymeric nano/microparticles with encapsulated drug that can be applied for maximize therapeutic activity and minimizes undesirable effects. However, these processes entail several conditions to operate efficiently. They present high sensibility to changes in temperature, flow rate, pressure, and chemical solution composition. An optimal configuration of these parameters is required to guarantee stable particle production. For these reasons, integration of technological devices like sensors, actuators, microfluidic devices and control systems is essential to increase particle production performance. The proposal of this work is to develop an integrated monitored and controlled system using LTCC (Low Temperature Co-Fired Ceramic) microreactors to generate polymeric nano/microparticles for encapsulation of hydrocortisone drug with PCL and Pluronic polymers. The microfluidic integrated system is developed through devices integration, system characterization and control loops configuration, using pressure sensors, syringe and microgear pumps, mixer and vortex LTCC microfluidic reactors, communication drivers, and data processing/control programs. Dynamic Light Scattering, Optical and Scanning Electron Microscopy were employed to measure particle size, polydispersity (PdI) distribution and particle morphology. Preliminary results showed nano/microparticles with encapsulated hydrocortisone drug having a mean diameter size of 528-816 nm and Polidispersity Index (PdI) < 0.5.
机译:纳米技术基于聚合物纳米/微粒的制备,用于制造具有包封的药物的药物递送系统(DDS)的方法和方法,其可用于最大化治疗活性并最大限度地减少不期望的效果。但是,这些过程需要有效运行的若干条件。它们对温度,流速,压力和化学溶液组合物的变化具有很高的敏感性。需要提供这些参数的最佳配置来保证稳定的颗粒生产。由于这些原因,技术设备的整合等传感器,致动器,微流体装置和控制系统对于提高粒子生产性能至关重要。这项工作的提议是使用LTCC(低温共烧陶瓷)微反应器开发集成的监测和控制系统,以产生聚合物纳米/微粒,用于用PCL和Pluronic聚合物包封氢化可的松药物。微流体集成系统是通过设备集成,系统特征和控制回路配置,使用压力传感器,注射器和微内器泵,混合器和涡流LTCC微流体反应堆,通信驱动程序和数据处理/控制程序。使用动态光散射,光学和扫描电子显微镜测量粒度,多分散性(PDI)分布和颗粒形态学。初步结果显示纳米/微粒,其封装的氢化胞松子药物的平均直径尺寸为528-816nm和Polidpersity指数(PDI)<0.5。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号